Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
<iframe src="https://hindustansphere.com/embed/cluster/fe27419facd8769b87205ebe7421c1f6f688ba05" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark"></iframe>
Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
